13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01777412 (ClinicalTrials.gov) | June 2013 | 21/1/2013 | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Bevacizumab | Johns Hopkins University | Genentech, Inc.;Guthy Jackson Charitable Foundation | Completed | 18 Years | 70 Years | All | 10 | Phase 1 | United States |